April 11 Leap Therapeutics announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12.66M shares of its common stock at a price of $2.82 per share and pre-funded warrants to purchase 1.52M shares of common stock at a price of $2.819 per share of common stock issuable upon exercise of the pre-funded warrants, in a private placement. Leap anticipates the gross proceeds from the private placement will be approxi...
$Leap Therapeutics(LPTX.US)$ NEWS LEAP THERAPEUTICS ANNOUNCES $40 MILLION PRIVATE PLACEMENT INTENDS TO USE NET PROCEEDS FROM FINANCING TO FUND CONTINUED DEVELOPMENT OF ITS LEAD MONOCLONAL ANTIBODY PROGRAM, DKN-01
$Leap Therapeutics(LPTX.US)$Leap Therapeutics Concludes Enrollment In The Randomized Controlled Part C Of Distinguish Study Of DKN-01 In Combination With BeiGene's Tislelizumab And Chemotherapy In Patients With Advanced Gastroesophageal Junction And Gastric Cancer Benzinga· 1 min ago
Jaguar8 : 喜歡它
Trytosaveabit樓主 Jaguar8: 對!吉利亞在做什麼?嘿河
Jaguar8 Trytosaveabit樓主: 我覺得他們最終會買到這個
买跌不追涨 : 今天可以早點休息吧,別這麼累。週末愉快
BelleWeather : 有趣的選擇。我將以科學為重點做 DD。我希望它能夠成功,他們會被買掉
查看更多評論...